Open-Label, Dose-Escalation Trial to Evaluate the Safety,Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies
A study for patients with advanced cancers using oral study drug MGCD265
Sponsor: Mirati Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAP0559
U.S. Govt. ID: NCT00697632
Contact: Victoria Vulaj: 646-317-6041 / vv2218@columbia.edu
Additional Study Information: The goal of this clinical research study is to find the highest safe dose of the drug MGCD265 thatcan be given to patients with advanced cancer. The safety of this drug, and the effect that it hason your disease and your body will also be studied.MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow.MGCD265 also prevents the growth of new blood vessels that help cancer tumors grow andspread. MGCD265 an investigational agent. This means that MGCD265 is not approved by theFood and Drug Administration (FDA).
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have an advanced cancer that is currently incurable with standard therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Victoria Vulaj
vv2218@columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE